{"url_path":"/sec/btcy/10-k/2026/item-12","section_key":"item-12","section_title":"Item 12 SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS**","topic":"sec","document":{"doc_type":"10-K","doc_date":"2026-07-14","source_url":"https://www.sec.gov/Archives/edgar/data/1630113/0001493152-26-033207-index.html","accession_number":"0001493152-26-033207","cik":"0001630113","ticker":"BTCY","issuer_name":"BIOTRICITY INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1630113/0001493152-26-033207-index.html","primary_entity_key":"0001630113","primary_entity_name":"BIOTRICITY INC."},"word_count":550,"has_tables":true,"body_markdown":"**ITEM\n12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS**\n\n \n\nThe\nfollowing table shows the beneficial ownership of our common stock as of July 14, 2026 held by (i) each affiliated person known to us\nto be the beneficial owner of more than five percent of our common stock; (ii) each director; (iii) each executive officer; and (iv)\nall directors, director nominees and executive officers as a group.\n\n \n\nBeneficial\nownership is determined in accordance with the rules of the SEC, and generally includes voting power and/or investment power with respect\nto the securities held. Shares of common stock subject to options and warrants currently exercisable or which may become exercisable\nwithin 60 days of July 14, 2026 are deemed outstanding and beneficially owned by the person holding such options or warrants for purposes\nof computing the number of shares and percentage beneficially owned by such person, but are not deemed outstanding for purposes of computing\nthe percentage beneficially owned by any other person. Except as indicated in the footnotes to this table, the persons or entities named\nhave sole voting and investment power with respect to all shares of our common stock shown as beneficially owned by them.\n\n \n\nThe following table assumes 15,092,233 shares are outstanding as of July\n14, 2026, consisting of 14,931,551 shares of common stock and 160,672 Exchangeable Share common stock equivalents. These amounts and the\npercentages below assume the exchange by all of the holders of Exchangeable Shares of iMedical for an equal number of shares of our common\nstock in accordance with the terms of the Exchangeable Shares. Shares of common stock subject to options, warrants or convertible securities\nexercisable or convertible within 60 days of July 14, 2026 and Series C Preferred shares are deemed outstanding for computing the percentage\nof the person or entity holding such options, warrants or convertible securities but are not deemed outstanding for computing the percentage\nof any other person; calculations are based on a residual 15,092,233 shares of common stock issued and outstanding on a fully diluted\nbasis, after exchanges, as of July 14, 2026, as well as 335 shares of Series B preferred stock issued and outstanding as of July 14, 2026\nand 2,112,509 of Series C Preferred stock issued and outstanding or to be issued as of July 14, 2026.\n\n \n\nName\nof Beneficial Owner (1) \n\n**Shares\nof**\n\n**Series\nC**\n\n**Preferred**\n\n**Stock**\n\n**Beneficially**\n\n**Owned\n(2)**\n  \n\n**%\nof Shares**\n\n**of\nSeries C**\n\n**Preferred**\n\n**Stock**\n\n**Beneficially**\n\n**Owned**\n  \n\n**Shares\nof**\n\n**Common**\n\n**Stock**\n\n**Beneficially**\n\n**Owned**\n  \n\n**%\nof Shares**\n\n**of\nCommon**\n\n**Stock**\n\n**Beneficially**\n\n**Owned**\n \n\nWaqaas Al-Siddiq \n 538,178  \n 25.2% \n -  \n * \n\nJohn Ayanoglou \n 94,316  \n 4.54% \n -  \n * \n\nDave Rosa \n 23,469  \n \n1.1\n  \n -  \n *%\n\nJainal Bhuiyan \n 22,077  \n 1.0% \n -  \n * \n\nRon McClurg \n 32,210  \n 1.5% \n -  \n * \n\nSohaira Siddiqui \n 196,517  \n 9.32% \n -  \n * \n\nMohammad Siddiqui \n 189,816  \n \n8.9\n% \n -  \n * \n\nRizwana Siddiqui \n 195,390  \n 9.1% \n -  \n * \n\nRizwan Rahman \n 179,043  \n 8.4% \n -  \n * \n\nAll directors and executive\nofficers as a group (5 person) \n 710,250  \n 33.25% \n      -  \n 0.0%\n\n \n\n*\nLess than 1%\n\n \n\n(1)\nUnless otherwise noted, the address of each person listed is c/o Biotricity, Inc., 203 Redwood Shores Parkway, Suite 600 Redwood City,\nCalifornia 94065\n\n \n\n(2) Each share of Series C Preferred Stock has voting rights equivalent\nto 40 Common Stock votes. This table is based on 2,112,509 shares of Series C Preferred stock issued and outstanding on July 14, 2026."}